THERAPY FOR CHAGAS DISEASE IN BABOON MODEL

狒狒模型治疗恰加斯病

• 批准号: 8172726
• 负责人: JOHN L VANDEBERG
• 金额: $ 13.43万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172726
• 关键词: Adolescent; Affect; Animals; Antifungal Agents; Biopsy; Blood; Cardiac; Chagas Disease; Communicable Diseases; Computer Retrieval of Information on Scientific Projects Database; Disease; Funding; Grant; Health Status; Heart; Human; Immune system; Infection; Infectious Diseases Research; Institution; Latin America; Macaca mulatta; Modeling; Morbidity - disease rate; Mus; Pan Genus; Papio; Parasites; Pathology; Pharmaceutical Preparations; Primates; Research; Research Personnel; Resources; Source; South America; United States National Institutes of Health; drug testing; improved; mortality; nonhuman primate; posaconazole; research study; success; sucking

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chagas disease is caused by a parasite that is carried by a blood-sucking bug that is endemic in Central and South America and in southern U.S. This disease causes perturbations in the immune system and it causes cardiac pathology. Infected primates should not be used for studies in infectious disease research or cardiac research. At the SNPRC 2% of baboons, 4% of rhesus macaques and 12% of chimpanzees are infected. We know that this infection also is endemic at at least some of the other primate facilities in the southern U.S. There is no treatment for Chagas disease. The initial infection in animals or humans persists lifelong. However, posaconazole, a new drug that is approved as an anti-fungal for human use, has demonstrated a high level of efficacy in eliminating the parasites in treatment of mice that were experimentally infected with the parasite. We are testing this drug in a study involving naturally infected baboons for its efficacy in eliminating the parasite. The experiment will involve endomyocardial biopsy at the beginning and at the end of the study so that parasite levels in the heart and pathological progression can be determined. If the treatment is successful, we expect that its use at primate facilities in southern U.S. will decrease morbidity and mortality among juveniles and breeders, and will increase the number of animals available for research on infectious diseases. Even if the treatment is only partially successful, the health status of infected animals may improve. Furthermore, if the experiment achieves at least partial success, the results will demonstrate the utility of nonhuman primates as models for developing treatments for Chagas disease, which affects 10 million people in Latin America and an estimated 100,000 people in the U.S., as well as an undetermined number of nonhuman primates in the southern U.S.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 恰加斯病是由吸血虫携带的寄生虫引起的，这种寄生虫在中美洲、南美洲以及美国南部流行。这种疾病会导致免疫系统紊乱，并引起心脏病。 受感染的灵长类动物不应用于传染病研究或心脏研究。 在 SNPRC，2% 的狒狒、4% 的恒河猴和 12% 的黑猩猩受到感染。 我们知道，这种感染至少在美国南部的一些其他灵长类动物设施中也很流行。查加斯病尚无治疗方法。 动物或人类的初始感染会持续终生。 然而，泊沙康唑是一种被批准作为人类抗真菌药物的新药，在治疗实验性感染寄生虫的小鼠时，显示出高水平的消除寄生虫的功效。 我们正在一项涉及自然感染狒狒的研究中测试这种药物消除寄生虫的功效。 该实验将在研究开始和结束时进行心内膜心肌活检，以便确定心脏中的寄生虫水平和病理进展。 如果治疗成功，我们预计在美国南部灵长类动物设施中的使用将降低幼年灵长类动物和饲养者的发病率和死亡率，并将增加可用于传染病研究的动物数量。 即使治疗仅部分成功，受感染动物的健康状况也可能会改善。 此外，如果该实验至少取得部分成功，结果将证明非人类灵长类动物作为开发恰加斯病治疗方法的模型的效用，这种疾病影响拉丁美洲的 1000 万人，估计在美国有 10 万人，以及美国南部数量不明的非人类灵长类动物。